Interview Highlights From ASH's 2025 Meeting

“I think we're entering an age where cellular therapy is probably the most effective therapy for a lot of hematologic malignancies, especially multiple myeloma, and expanding the indications and the treatment population that we can use it for I think is super treatment-relevant.”

From December 6 to 9, 2025, physicians, industry executives, patient advocates, and various other experts from across the fields of hematology, oncology, and more gathered at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 6 to 9, 2025, in Orlando, Florida, to discuss the latest research and breakthroughs in the field. CGTLive® was on the ground at the meeting, speaking to various experts in cell therapy, gene therapy, and immunotherapy about some of the key presentations and sessions in those niches that were held at the conference.

In these highlight reel, we showcased snippets from interviews with Deevyashali Parekh, MBBS, an internal medicine resident at SUNY Upstate Medical University Hospital; Steven W. Pipe, MD, a professor of pediatric hematology/oncology at the University of Michigan Health; and Janna Minehart, MD, a clinical fellow in hematology oncology (Master of Science Translational Research Program) at the University of Pennsylvania, and the cohost of CGTLive’s own ImmunoLogic video podcast.

Parekh’s interview focused on his presentation of a study on real-world data from patients with renal failure who received treatment with chimeric antigen receptor T-cell (CAR-T) therapy. Meanwhile, Pipe’s interview covered his presentation of end-of-study data from the pivotal phase 3 HOPE-B clinical trial (NCT03569891), which evaluated CSL Behring/uniQure’s etranacogene dezaparvovec (marketed as Hemgenix), a gene therapy product for the treatment of severe or moderately severe hemophilia B with or without preexisting AAV5 neutralizing antibodies (NAbs). Minehart’s interview covered a variety of presentations on immunotherapy in oncology that she attended at the conference, which she viewed as some of her personal highlights.

For more coverage of ASH 2025, click here.